Australia: Seven commandments of continuous disclosure

Services: Corporate & Commercial
Industry Focus: Life Sciences & Healthcare

What you need to know

  • The ASX Listing Rules require ASX-listed companies to "immediately" disclose to the ASX any information concerning them "that a reasonable person would expect to have a material effect on the price or value" of their securities.
  • Given their inherent scientific and regulatory complexities, life sciences companies must be particularly careful to disclose all required information in terms that are clearly understood by investors, allowing them to assess the commercial significance of that information.
  • We suggest seven 'commandments' for companies considering how best to meet their disclosure obligations.

Obtaining listing on the ASX is an exciting milestone for any company. It also carries with it some important obligations including the requirement to give 'continuous disclosure'.

In this article we explore practical compliance with ASX continuous disclosure requirements in the particular context of the life sciences industry. We then suggest 'seven commandments' to assist life sciences companies in understanding and meeting their continuous disclosure obligations.

Immediate and balanced disclosure

ASX Listing Rule 3.1 requires that ASX-listed companies "immediately" disclose to the ASX any information concerning them "that a reasonable person would expect to have a material effect on the price or value" of their securities.

ASX Guidance Note 8 explains the "immediate" disclosure requirement as a requirement to disclose "promptly and without delay".

In practice, this means that companies need to be both proactive and reactive to ensure they meet their disclosure obligations. Being appropriately reactive means sufficiently monitoring publicly available information regarding their securities, including any commentary in major newspapers and social media, to promptly respond to market rumours or any loss of confidentiality.

The social media landscape in particular has the potential to throw up tricky issues for life sciences companies conducting clinical trials, given the risk that the trial participants may make claims or statements to which a company might need to respond. This is precisely the scenario that Neuren Pharmaceuticals faced a few years ago when, part way through its Phase 2 clinical trial of a drug to treat adolescents and adults with Rett Syndrome (a severe genetic disorder of the nervous system), some of the participants' parents posted comments on social media about the positive effect the drug was having on their children. As a result, Neuren Pharmaceuticals issued a clarifying statement in August 2013:

[Neuren] would like to assure the market that these comments reflect subjective impressions that have not been validated by analysis of clinical data. In particular, we would like to reiterate that, as the study is a randomized, double-blind trial, neither Neuren, the clinical investigators nor the parents can be or are aware of the treatment assignment (NNZ-2566 or placebo) for any subject. To the best of our knowledge, the blinded nature of the trial has not been compromised. The clinical benefit, if any, of NNZ-2566 compared to placebo will not be known until treatment assignment is unblinded and the trial data are analysed. Neuren will communicate the results of that analysis when it has been completed and reviewed by the appropriate parties, which is anticipated to be in the second half of 2014.

The events that unfolded for Neuren are a clear illustration of the need for life sciences companies to keep close tabs on public discussion or debate about their business activities, and be ready to respond when required.

It is also important for companies to consider the expectations of the 'reasonable person' in determining what is to be announced. Companies should not 'cherry pick' information – for example, by publishing positive but not negative results of clinical trials. If a company needs time to assess the impact of new developments, it can request a trading halt to do so.

When you can hold back

Under Listing Rule 3.1A, a company is excused from disclosure when all of the following three requirements are satisfied:

  • at least one of the following five situations applies:
    • disclosure would break the law
    • the information relates to an incomplete proposal or negotiation
    • the information comprises matters of supposition or is insufficiently definite
    • the information is prepared for internal management purposes
    • the information is a trade secret
  • the informtion is confidential; and
  • a reasonable person would not expect the information to be disclosed.

These exemption criteria must be considered with care, as there are significant consequences of getting it wrong and failing to disclose something that should have been disclosed.

The cost of getting it wrong

The Corporations Act 2001 (Cth) (Corporations Act) imposes penalties for failure to disclose in accordance with the Listing Rules. In particular:

  • Individuals involved in the failure may face criminal charges with a fine of up to $36,000 and/or up to five years imprisonment,1 or a civil penalty fine of up to $200,000,2 unless they took reasonable steps to ensure the company complied with its disclosure obligations and had reasonable grounds to believe it did.
  • The company itself may face a civil penalty fine of up to $1 million.3 Alternatively, ASIC may issue an infringement notice to the company,4 attracting a fine of between $33,000 and $100,000 depending on the company's size, type and track record.5

Failure to disclose may also attract class action suits against the company.

Specific guidance for life sciences companies

Acknowledging that life sciences companies routinely engage in activities that can throw the continuous disclosure requirement into stark light, the ASX and AusBiotech have jointly published an industry-specific guide to disclosure for Australian listed life sciences companies. This is known as the "Code of Best Practice for Reporting by Life Science Companies" (Code).

Now in its second edition, the Code provides a recommended disclosure framework around the key drivers of value for life sciences companies, including R&D, clinical trials, intellectual property and manufacturing. It offers guidance on the circumstances in which disclosure obligations might apply and the level of detail required, as well as explanations of various technical terms. Here are some highlights:

  • Companies should bear in mind the importance of ensuring their announcements are clear, particularly since many investors will have a limited understanding of the science underlying their activities. Announcements should explain the implications of the information disclosed and thus facilitate the evaluation of its significance.
    For example, when reporting on clinical trials, companies should clearly explain how the study is linked to the relevant regulatory process so that investors understand the trial's commercial or regulatory significance. Trial results should be disclosed with reference to the initial goals (were the endpoints achieved?), structure and key aspects of the trial protocol.
  • Companies whose activities are primarily in the R&D space are encouraged by the Code to provide periodic reports to the market (at least half yearly) on their R&D activities in the preceding period, including a summary of related expenditure. Information regarding R&D activities needs to be fair and balanced so that investors can assess the commercial prospects of the proposed or pipeline product.
  • It is common for life sciences companies to enter into licensing arrangements, co-marketing agreements, joint ventures or similar engagements for various commercial or other reasons. In disclosing these types of arrangements, companies need to balance commercial sensitivity with the need to enable investors to properly assess the value of the relevant arrangement or transaction. This requires proactive engagement with the other party as to the content of announcements.

Seven commandments

The practical implications of the continuous disclosure requirement will look different for every company.

As a starting point, we suggest these 'seven commandments' to guide companies in meeting their disclosure obligations:

1. Be quick: Understand the need to disclose market sensitive information "immediately".

2. Be savvy: Understand the exceptions to disclosure.

3. Be fair: Don't cherry pick your disclosures (for example, don't rush to share the good news and hold back the bad).

4. Be prepared: Have a protocol for preparing and signing off updates to the market, and use trading halts to give yourself time if you need it.

5. Be appropriately proactive and reactive: At each board meeting, ask 'have we decided anything today that ought to be disclosed?' Also ensure there are sufficient measures in place to monitor the media and identify issues that might require a response.

6. Be commercial: Consider the company's key drivers of value in determining what should be disclosed.

7. Be practical: Don't just provide information, but explain its implications for the company and unpack its significance if there is dense scientific or technical content involved.

While the details and intricacies about the continuous disclosure regime can sometimes be overwhelming, a common sense approach that draws upon these seven commandments should go a long way towards helping life sciences companies communicate well with the market.

Footnotes
1Corporations Act 2001 (Cth) s 1311(1), Schedule 3; Crimes Act 1914 (Cth) s 4AA(1).
2Corporations Act s 1317E, 1317G(1B)(a).
3Corporations Act s 1317E, 1317G(1B)(b).
4Corporations Act s 1317DAC.
5Corporations Act s 1317DAE(2)-(7).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.